Nipocalimab
J&J’s Nipocalimab Shows Promise in Sjögren’s Disease with Significant Phase 2 Results
nipocalimab, Sjögren’s disease, Johnson & Johnson, Phase 2 study, autoimmune disease, FcRn inhibitor
J&J’s Nipocalimab Demonstrates Positive Phase III and Phase II Results in Autoimmune Disorders
Nipocalimab, Sjogren’s Syndrome, Johnson and Johnson, Autoimmune Diseases, Myasthenia Gravis, Generalized, Clinical Research, Erythroblastosis, Fetal